ARWR, NasdaqGS
Arrowhead Pharmaceuticals, Inc. (ARWR)
Price (as of October 25)
31.32USD
Correlations
Lowest within Industry
| Symbol | Correlation |
|---|---|
|
CureVac N.V. |
-0.4 |
|
Compass Therapeutics, Inc. |
-0.31 |
|
Chemomab Therapeutics Ltd. |
-0.3 |
|
Corcept Therapeutics Incorporated |
-0.28 |
|
Ikena Oncology, Inc. |
-0.28 |
|
DICE Therapeutics, Inc. |
-0.12 |
|
Akouos, Inc. |
-0.11 |
|
Annexon, Inc. |
-0.11 |
|
Crinetics Pharmaceuticals, Inc. |
-0.11 |
|
Daré Bioscience, Inc. |
0.02 |
Highest within Industry
| Symbol | Correlation |
|---|---|
|
Arcturus Therapeutics Holdings Inc. |
0.85 |
|
Arvinas, Inc. |
0.85 |
|
Atara Biotherapeutics, Inc. |
0.79 |
|
Atai Life Sciences N.V. |
0.77 |
|
Ascendis Pharma A/S |
0.76 |
|
Ardelyx, Inc. |
0.13 |
|
Arcutis Biotherapeutics, Inc. |
0.4 |
|
AnaptysBio, Inc. |
0.12 |
|
ALX Oncology Holdings Inc. |
0.41 |
|
Artelo Biosciences, Inc. |
0.13 |
Lowest within Industry
| Symbol | Correlation |
|---|---|
|
Arcellx, Inc. |
-0.19 |
|
ImmuCell Corporation |
-0.16 |
|
Akouos, Inc. |
-0.15 |
|
Achieve Life Sciences, Inc. |
-0.15 |
|
HOOKIPA Pharma Inc. |
-0.14 |
|
Annexon, Inc. |
-0.11 |
|
Chemomab Therapeutics Ltd. |
0.02 |
|
Biohaven Ltd. |
0.02 |
|
Acurx Pharmaceuticals, Inc. |
-0.03 |
|
DICE Therapeutics, Inc. |
-0.12 |
Highest within Industry
| Symbol | Correlation |
|---|---|
|
Arvinas, Inc. |
0.63 |
|
Atara Biotherapeutics, Inc. |
0.61 |
|
Allogene Therapeutics, Inc. |
0.6 |
|
Arcturus Therapeutics Holdings Inc. |
0.59 |
|
Arcutis Biotherapeutics, Inc. |
0.58 |
|
ALX Oncology Holdings Inc. |
0.41 |
|
argenx SE |
0.27 |
|
Ascendis Pharma A/S |
0.17 |
|
AnaptysBio, Inc. |
0.12 |
|
Applied Molecular Transport Inc. |
0.34 |
Lowest within Industry
| Symbol | Correlation |
|---|---|
|
Arcellx, Inc. |
-0.19 |
|
DICE Therapeutics, Inc. |
-0.12 |
|
Akouos, Inc. |
-0.11 |
|
Crinetics Pharmaceuticals, Inc. |
-0.11 |
|
Akero Therapeutics, Inc. |
-0.11 |
|
Annexon, Inc. |
-0.11 |
|
Humacyte, Inc. |
-0.09 |
|
Applied Therapeutics, Inc. |
-0.07 |
|
GreenLight Biosciences Holdings |
-0.07 |
|
Finch Therapeutics Group, Inc. |
-0.07 |
Highest within Industry
| Symbol | Correlation |
|---|---|
|
Atara Biotherapeutics, Inc. |
0.41 |
|
ALX Oncology Holdings Inc. |
0.41 |
|
Arcutis Biotherapeutics, Inc. |
0.4 |
|
Atai Life Sciences N.V. |
0.4 |
|
Alnylam Pharmaceuticals, Inc. |
0.39 |
|
AlloVir, Inc. |
0.38 |
|
Arvinas, Inc. |
0.37 |
|
Allogene Therapeutics, Inc. |
0.35 |
|
Applied Molecular Transport Inc. |
0.34 |
|
Ascendis Pharma A/S |
0.17 |
Lowest within Industry
| Symbol | Correlation |
|---|---|
|
Arcellx, Inc. |
-0.19 |
|
DICE Therapeutics, Inc. |
-0.12 |
|
Akouos, Inc. |
-0.11 |
|
Crinetics Pharmaceuticals, Inc. |
-0.11 |
|
Akero Therapeutics, Inc. |
-0.11 |
|
Annexon, Inc. |
-0.11 |
|
Humacyte, Inc. |
-0.09 |
|
Applied Therapeutics, Inc. |
-0.07 |
|
GreenLight Biosciences Holdings |
-0.07 |
|
Finch Therapeutics Group, Inc. |
-0.07 |
Highest within Industry
| Symbol | Correlation |
|---|---|
|
ALX Oncology Holdings Inc. |
0.41 |
|
Arcutis Biotherapeutics, Inc. |
0.4 |
|
Atai Life Sciences N.V. |
0.4 |
|
AlloVir, Inc. |
0.38 |
|
Arvinas, Inc. |
0.37 |
|
Allogene Therapeutics, Inc. |
0.35 |
|
Applied Molecular Transport Inc. |
0.34 |
|
argenx SE |
0.27 |
|
Alzamend Neuro, Inc. |
0.23 |
|
Atara Biotherapeutics, Inc. |
0.23 |
Lowest by Sector
| Symbol | Correlation |
|---|---|
|
CureVac N.V. |
-0.4 |
|
Compass Therapeutics, Inc. |
-0.31 |
|
Chemomab Therapeutics Ltd. |
-0.3 |
|
McKesson Corporation |
-0.3 |
|
Corcept Therapeutics Incorporated |
-0.28 |
|
Ikena Oncology, Inc. |
-0.06 |
|
DICE Therapeutics, Inc. |
-0.12 |
|
Clever Leaves Holdings Inc. |
0 |
|
Akouos, Inc. |
-0.11 |
|
Annexon, Inc. |
-0.11 |
Highest by Sector
| Symbol | Correlation |
|---|---|
|
Arcturus Therapeutics Holdings Inc. |
0.85 |
|
Arvinas, Inc. |
0.85 |
|
Atara Biotherapeutics, Inc. |
0.79 |
|
Atai Life Sciences N.V. |
0.77 |
|
Ascendis Pharma A/S |
0.76 |
|
Ardelyx, Inc. |
0.13 |
|
Arcutis Biotherapeutics, Inc. |
0.4 |
|
Alphatec Holdings, Inc. |
0.08 |
|
Asensus Surgical, Inc. |
0.02 |
|
Accuray Incorporated |
0.14 |
Lowest by Sector
| Symbol | Correlation |
|---|---|
|
Arcellx, Inc. |
-0.19 |
|
ImmuCell Corporation |
-0.16 |
|
Akouos, Inc. |
-0.15 |
|
Achieve Life Sciences, Inc. |
-0.15 |
|
HOOKIPA Pharma Inc. |
-0.14 |
|
Annexon, Inc. |
-0.11 |
|
Dynavax Technologies Corporation |
0.01 |
|
DocGo Inc. |
-0.13 |
|
Chemomab Therapeutics Ltd. |
0.02 |
|
McKesson Corporation |
-0.01 |
Highest by Sector
| Symbol | Correlation |
|---|---|
|
Arvinas, Inc. |
0.63 |
|
Atara Biotherapeutics, Inc. |
0.61 |
|
Allogene Therapeutics, Inc. |
0.6 |
|
Arcturus Therapeutics Holdings Inc. |
0.59 |
|
Arcutis Biotherapeutics, Inc. |
0.58 |
|
ALX Oncology Holdings Inc. |
0.41 |
|
Asensus Surgical, Inc. |
0.02 |
|
argenx SE |
0.27 |
|
Ascendis Pharma A/S |
0.17 |
|
American Well Corporation |
0.4 |
Lowest by Sector
| Symbol | Correlation |
|---|---|
|
Arcellx, Inc. |
-0.19 |
|
DocGo Inc. |
-0.13 |
|
DICE Therapeutics, Inc. |
-0.12 |
|
Akouos, Inc. |
-0.11 |
|
Crinetics Pharmaceuticals, Inc. |
-0.11 |
|
Akero Therapeutics, Inc. |
-0.11 |
|
Annexon, Inc. |
-0.11 |
|
Humacyte, Inc. |
-0.09 |
|
Global Cord Blood Corporation |
-0.04 |
|
Applied Therapeutics, Inc. |
-0.07 |
Highest by Sector
| Symbol | Correlation |
|---|---|
|
Atara Biotherapeutics, Inc. |
0.41 |
|
ALX Oncology Holdings Inc. |
0.41 |
|
Arcutis Biotherapeutics, Inc. |
0.4 |
|
American Well Corporation |
0.4 |
|
Atai Life Sciences N.V. |
0.4 |
|
Alnylam Pharmaceuticals, Inc. |
0.18 |
|
AlloVir, Inc. |
0.38 |
|
Arvinas, Inc. |
0.37 |
|
Allogene Therapeutics, Inc. |
0.35 |
|
Applied Molecular Transport Inc. |
0.34 |
Lowest by Sector
| Symbol | Correlation |
|---|---|
|
Arcellx, Inc. |
-0.19 |
|
DocGo Inc. |
-0.13 |
|
DICE Therapeutics, Inc. |
-0.12 |
|
Akouos, Inc. |
-0.11 |
|
Crinetics Pharmaceuticals, Inc. |
-0.11 |
|
Akero Therapeutics, Inc. |
-0.11 |
|
Annexon, Inc. |
-0.11 |
|
Humacyte, Inc. |
-0.09 |
|
Applied Therapeutics, Inc. |
-0.07 |
|
GreenLight Biosciences Holdings |
-0.07 |
Highest by Sector
| Symbol | Correlation |
|---|---|
|
ALX Oncology Holdings Inc. |
0.41 |
|
Arcutis Biotherapeutics, Inc. |
0.4 |
|
American Well Corporation |
0.4 |
|
Atai Life Sciences N.V. |
0.4 |
|
AlloVir, Inc. |
0.38 |
|
Arvinas, Inc. |
0.37 |
|
Allogene Therapeutics, Inc. |
0.35 |
|
Applied Molecular Transport Inc. |
0.34 |
|
Aquestive Therapeutics, Inc. |
0.28 |
|
argenx SE |
0.27 |
Lowest Overall
| Symbol | Correlation |
|---|---|
|
CureVac N.V. |
-0.4 |
|
German American Bancorp, Inc. |
-0.37 |
|
Gores Holdings IX, Inc. |
-0.35 |
|
Huron Consulting Group Inc. |
-0.35 |
|
FTAC Parnassus Acquisition Corp. |
-0.35 |
|
AirNet Technology Inc. |
0.01 |
|
DIRTT Environmental Solutions Ltd. |
-0.01 |
|
Dingdong (Cayman) Limited |
-0.09 |
|
Anzu Special Acquisition Corp I |
-0.02 |
|
Compass Therapeutics, Inc. |
0.02 |
Highest Overall
| Symbol | Correlation |
|---|---|
|
Arcturus Therapeutics Holdings Inc. |
0.85 |
|
Arvinas, Inc. |
0.85 |
|
ARK Genomic Revolution ETF |
0.83 |
|
Atara Biotherapeutics, Inc. |
0.79 |
|
Atai Life Sciences N.V. |
0.77 |
|
Ascendis Pharma A/S |
0.17 |
|
Ardelyx, Inc. |
0.13 |
|
ARK Autonomous Technology & Robotics ETF |
0.3 |
|
ARK Space Exploration & Innovation ETF |
0.56 |
|
First Trust IndxxMetaverse ETF |
0.7 |
Lowest Overall
| Symbol | Correlation |
|---|---|
|
Gores Holdings IX, Inc. |
-0.33 |
|
FutureTech II Acquisition Corp. |
-0.25 |
|
Genius Group Limited |
-0.21 |
|
AirNet Technology Inc. |
-0.2 |
|
Optica Rare Earths & Critical Materials ETF |
-0.2 |
|
Preferred Apartment Communities, Inc. |
-0.04 |
|
SailPoint Technologies Holdings, Inc. |
-0.02 |
|
FTAC Parnassus Acquisition Corp. |
-0.08 |
|
Aurora Technology Acquisition Corp. |
-0.19 |
|
Arcellx, Inc. |
-0.19 |
Highest Overall
| Symbol | Correlation |
|---|---|
|
ARK Genomic Revolution ETF |
0.78 |
|
First Trust IndxxMetaverse ETF |
0.7 |
|
ARK Autonomous Technology & Robotics ETF |
0.67 |
|
ARK Space Exploration & Innovation ETF |
0.66 |
|
Arvinas, Inc. |
0.63 |
|
AI Quality Growth ETF |
0.62 |
|
Atara Biotherapeutics, Inc. |
0.23 |
|
Allogene Therapeutics, Inc. |
0.35 |
|
Arcturus Therapeutics Holdings Inc. |
0.13 |
|
Arcutis Biotherapeutics, Inc. |
0.4 |
Lowest Overall
| Symbol | Correlation |
|---|---|
|
Gores Holdings IX, Inc. |
-0.33 |
|
FutureTech II Acquisition Corp. |
-0.25 |
|
Genius Group Limited |
-0.21 |
|
Optica Rare Earths & Critical Materials ETF |
-0.2 |
|
Aurora Technology Acquisition Corp. |
-0.19 |
|
Arcellx, Inc. |
-0.19 |
|
Dakota Gold Corp. |
-0.18 |
|
Catalyst Bancorp, Inc. |
-0.17 |
|
Dimensional International Core Equity 2 ETF |
-0.16 |
|
Globalink Investment Inc. |
-0.16 |
Highest Overall
| Symbol | Correlation |
|---|---|
|
First Trust IndxxMetaverse ETF |
0.7 |
|
AI Quality Growth ETF |
0.62 |
|
ARK Space Exploration & Innovation ETF |
0.56 |
|
ARK Genomic Revolution ETF |
0.56 |
|
ARK Autonomous Technology & Robotics ETF |
0.48 |
|
Argo Blockchain plc |
0.46 |
|
QRAFT AI Enhanced U.S. Large Cap Momentum ETF |
0.44 |
|
Armor US Equity Index ETF |
0.42 |
|
Atara Biotherapeutics, Inc. |
0.23 |
|
Alkami Technology, Inc. |
0.41 |
Lowest Overall
| Symbol | Correlation |
|---|---|
|
Gores Holdings IX, Inc. |
-0.33 |
|
FutureTech II Acquisition Corp. |
-0.25 |
|
Genius Group Limited |
-0.21 |
|
Optica Rare Earths & Critical Materials ETF |
-0.2 |
|
Aurora Technology Acquisition Corp. |
-0.19 |
|
Arcellx, Inc. |
-0.19 |
|
Dakota Gold Corp. |
-0.18 |
|
Catalyst Bancorp, Inc. |
-0.17 |
|
Dimensional International Core Equity 2 ETF |
-0.16 |
|
Globalink Investment Inc. |
-0.16 |
Highest Overall
| Symbol | Correlation |
|---|---|
|
First Trust IndxxMetaverse ETF |
0.7 |
|
AI Quality Growth ETF |
0.62 |
|
ARK Space Exploration & Innovation ETF |
0.56 |
|
Argo Blockchain plc |
0.46 |
|
QRAFT AI Enhanced U.S. Large Cap Momentum ETF |
0.44 |
|
Armor US Equity Index ETF |
0.42 |
|
Alkami Technology, Inc. |
0.41 |
|
ALX Oncology Holdings Inc. |
0.41 |
|
Arcutis Biotherapeutics, Inc. |
0.4 |
|
American Well Corporation |
0.4 |
Profile
- Sector:
- Healthcare
- Industry:
- Biotechnology
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.